AstraZeneca to Sublicense Global Rights to Movantik to RedHill Biopharma
February 25 2020 - 2:41AM
Dow Jones News
By Adria Calatayud
AstraZeneca PLC said Tuesday that it has agreed to sublicense
global rights to its Movantik drug, a treatment for opioid-induced
constipation, to RedHill Biopharma Ltd.
AstraZeneca said RedHill will make an upfront payment of $52.5
million on closing and a further noncontingent payment of $15
million in 2021. The deal excludes Europe, Canada and Israel,
AstraZeneca said.
The FTSE 100-listed pharmaceutical company said Movantik
generated sales of $96 million in the U.S. last year. AstraZeneca
will continue to manufacture and supply Movantik to RedHill during
a transition period, it said.
The divestment is expected to be completed in the first quarter
of 2020, subject to closing conditions and regulatory clearances,
AstraZeneca said. The agreement won't affect AstraZeneca's
financial guidance for 2020, the company said.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
February 25, 2020 02:26 ET (07:26 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Redhill Biopharma (NASDAQ:RDHL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Redhill Biopharma (NASDAQ:RDHL)
Historical Stock Chart
From Sep 2023 to Sep 2024